马赛克HIV-1疫苗在APPROACH 1/2a期临床试验及恒河猴中的评估
APPROACH试验为多中心随机双盲安慰剂对照1/2a期研究,393名健康未感染HIV成人随机接受8种疫苗方案或安慰剂;该疫苗概念正在撒哈拉以南非洲开展2b期效力研究。
要点
- 马赛克Ad26/Ad26加高剂量gp140方案在人体中免疫原性最强,52周Env结合抗体应答率100%。
- 恒河猴中该方案诱导与人相似的免疫应答,并提供67%抗重复异源SHIV攻击保护。
- 所有疫苗方案安全耐受性良好,仅1%参与者报告至少1起与疫苗相关的3级不良事件。
核心结论
- 马赛克Ad26/Ad26加gp140 HIV-1疫苗在人体和恒河猴中诱导可比且稳健的免疫应答。
- 该疫苗在恒河猴中对重复异源SHIV攻击提供显著保护。
- 该疫苗概念正在撒哈拉以南非洲开展2b期临床效力研究(NCT03060629)。
研究设计与样本
- APPROACH为多中心、随机、双盲、安慰剂对照1/2a期试验,在东部非洲、南非、泰国和美国12家诊所招募18-50岁健康HIV-1未感染低风险参与者。
- 平行在72只恒河猴中随机分配至5种疫苗方案或安慰剂,评估对6次重复异源直肠内SHIV-SF162P3攻击的免疫原性和保护效力。
主要发现
- 所有疫苗方案均显示良好的安全性和耐受性;最常见征集性局部不良事件为轻至中度注射部位疼痛,不同活性组间为69%至88%,安慰剂组为49%。
- 393名参与者中5名(1%)报告至少1起被判定与疫苗相关的3级不良事件:腹痛和腹泻(同一参与者)、天冬氨酸转氨酶升高、体位性眩晕、背痛和不适。
- 马赛克Ad26/Ad26加高剂量gp140加强方案在人体中免疫原性最强,第52周Env特异性结合抗体应答率100%,抗体依赖性细胞吞噬应答率80%,第50周T细胞应答率83%。
- 恒河猴中Env特异性ELISA和酶联免疫斑点试验应答是抗SHIV攻击保护的主要免疫相关因素。
关键数值与推荐
- APPROACH试验中,马赛克Ad26/Ad26加高剂量gp140加强方案在人体第52周Env特异性结合抗体应答率为100%,抗体依赖性细胞吞噬应答率为80%。
- 该方案在人体第50周T细胞应答率为83%。
临床怎么用
- 该疫苗方案在人体中安全耐受且免疫原性强,支持推进至临床效力试验。
- 恒河猴中的保护数据和免疫相关因素为疫苗设计及效力评估提供了参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and preclinical studies. We aimed to evaluate mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel studies in humans and rhesus monkeys to define the optimal vaccine regimen to advance into clinical efficacy trials. METHODS: We conducted a multicentre, randomised, double-blind, placebo-controlled phase 1/2a trial (APPROACH). Participants were recruited from 12 clinics in east Africa, South Africa, Thailand, and the USA. We included healthy, HIV-1-uninfected participants (aged 18-50 years) who were considered at low risk for HIV-1 infection. We randomly assigned participants to one of eight study groups, stratified by region. Participants and investigators were blinded to the treatment allocation throughout the study. We primed participants at weeks 0 and 12 with Ad26.Mos.HIV (5 × 1010 viral particles per 0·5 mL) expressing mosaic HIV-1 envelope (Env)/Gag/Pol antigens and gave boosters at weeks 24 and 48 with Ad26.Mos.HIV or modified vaccinia Ankara (MVA; 108 plaque-forming units per 0·5 mL) vectors with or without high-dose (250 μg) or low-dose (50 μg) aluminium adjuvanted clade C Env gp140 protein. Those in the control group received 0·9% saline. All study interventions were administered intramuscularly. Primary endpoints were safety and tolerability of the vaccine regimens and Env-specific binding antibody responses at week 28. Safety and immunogenicity were also assessed at week 52. All participants who received at least one vaccine dose or placebo were included in the safety analysis; immunogenicity was analysed using the per-protocol population. We also did a parallel study in rhesus monkeys (NHP 13-19) to assess the immunogenicity and protective efficacy of these vaccine regimens against a series of six repetitive, heterologous, intrarectal challenges with a rhesus peripheral blood mononuclear cell-derived challenge stock of simian-human immunodeficiency virus (SHIV-SF162P3). The APPROACH trial is registered with ClinicalTrials.gov, number NCT02315703. FINDINGS: Between Feb 24, 2015, and Oct 16, 2015, we randomly assigned 393 participants to receive at least one dose of study vaccine or placebo in the APPROACH trial. All vaccine regimens demonstrated favourable safety and tolerability. The most commonly reported solicited local adverse event was mild-to-moderate pain at the injection site (varying from 69% to 88% between the different active groups vs 49% in the placebo group). Five (1%) of 393 participants reported at least one grade 3 adverse event considered related to the vaccines: abdominal pain and diarrhoea (in the same participant), increased aspartate aminotransferase, postural dizziness, back pain, and malaise. The mosaic Ad26/Ad26 plus high-dose gp140 boost vaccine was the most immunogenic in humans; it elicited Env-specific binding antibody responses (100%) and antibody-dependent cellular phagocytosis responses (80%) at week 52, and T-cell responses at week 50 (83%). We also randomly assigned 72 rhesus monkeys to receive one of five different vaccine regimens or placebo in the NHP 13-19 study. Ad26/Ad26 plus gp140 boost induced similar magnitude, durability, and phenotype of immune responses in rhesus monkeys as compared with humans and afforded 67% protection against acquisition of SHIV-SF162P3 infection (two-sided Fisher's exact test p=0·007). Env-specific ELISA and enzyme-linked immunospot assay responses were the principal immune correlates of protection against SHIV challenge in monkeys. INTERPRETATION: The mosaic Ad26/Ad26 plus gp140 HIV-1 vaccine induced comparable and robust immune responses in humans and rhesus monkeys, and it provided significant protection against repetitive heterologous SHIV challenges in rhesus monkeys. This vaccine concept is currently being evaluated in a phase 2b clinical efficacy study in sub-Saharan Africa (NCT03060629). FUNDING: Janssen Vaccines & Prevention BV, National Institutes of Health, Ragon Institute of MGH, MIT and Harvard, Henry M Jackson Foundation for the Advancement of Military Medicine, US Department of Defense, and International AIDS Vaccine Initiative.
引用
- Barouch DH, Tomaka FL, Wegmann F, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018. PMID: 30047376. doi:10.1016/S0140-6736(18)31364-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。